Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients
Lead SponsorInstituto Nacional de la Nutrición Salvador Zubiran
The purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (LBP) are correlated with PBMN pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. As a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on LBP, cytokines and infections in the same patients.
Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
Placebo capsules, one capsule per day during four weeks.
Inclusion Criteria: Cirrhosis Ascites No history of spontaneous bacterial peritonitis and/or < 1 g of protein in ascites No antibiotic use in previous 6 weeks Absence of infection (documented by clinical history, blood cytology, urinalysis and urine culture, thorax x-ray and paracentesis) Absence of GI bleeding or encephalopathy Signature of informed consent Exclusion Criteria: Ciprofloxacin contraindication Autoimmune hepatitis, sclerosing cholangitis or other autoimmune disease > 13 Child-Pugh points Inability to attend to regular visits Current alcohol intake Terminal disease with < 24 week expected survival